Producers of biosimilars – how to assess products, developments, and revenue prospects
What does the future hold for makers of biosimilar drugs? Visiongain's updated report shows you those companies' prospects to 2023. There you see results, trends, opportunities, and revenue predictions.
Our study analyses 25 leading developers, producers and marketers of biosimilars, also with discussion of other companies. There you find information on established and rising organisations. Discover their sales potentials.
That investigation is for everyone interested in the future of biopharmaceuticals. See now how you can benefit.
Forecasts and other data to help you stay ahead in knowledge of those biological drugs
In that report you find analytical profiles of top companies worldwide. There you analyse historical data, R&D, market shares, revenue forecasts, and growth rates. See qualitative analysis too for those biologics. You also gain 97 charts, 44 tables and an interview.
That work lets you assess the most lucrative parts of the industry for biosimilar drugs. Get revenue forecasts to 2023 for eight of the companies. See there how you can benefit your research, analyses, and decisions, also saving time.
Find where money lies for those protein-based medicines. The following sections explain what you get in that new analysis.
Companies based in regions with developed pharma industries
First, our study gives you discussions, financial analyses, and commercial outlooks for six biosimilar drug producers among the leading drug-producing countries:
• Sandoz
• Teva
• Hospira
• Stada Arzneimittel
• Medice Arzneimittel Pütter
• JCR Pharmaceuticals.
You see possibilities there for business performance. Discover what the future holds for those companies, including revenue predictions to 2023 for top firms. Hear too about other companies, including Actavis, Mylan, Pfizer, Boehringer Ingelheim, Mochida, and Nichi-Iko.
China – outlooks for leading biosimilar drug manufacturers
Next, our report analyses five Chinese biosimilar specialists:
• 3SBio
• Beijing SL Pharmaceutical
• GeneScience Pharmaceuticals
• Shanghai Fosun
• Tonghua Dongbao.
Many opportunities remain, with high, expanding revenues possible from 2013. See where best potentials exist.
India – prospects for leading players
You also discover outlooks for six Indian biosimilar specialists:
• Biocon
• Dr. Reddy's Laboratories
• Intas Biopharmaceuticals
• Reliance Life Sciences
• Wockhardt
• Zydus Cadila.
You also hear about activities of Ranbaxy, Cipla, and Lupin. Our report shows you how companies seize opportunities and expand their revenues.
Latin America – analysis of leading biological drug firms
Our new work also assesses four Latin American biosimilar drug producers:
• Probiomed
• Biosidus
• Amega Biotech
• Aché.
You find revenue data, trends, and opportunities there, seeing activities, product ranges, and prospects.
Producers from Central and Eastern Europe (CEE), Russian Federation, and South Korea
You also discover outlooks and activities of companies based in other developing countries:
• Bioton
• Pharmstandard
• LG Life Sciences
• Dong-A Pharmaceutical.
Developing and developed national markets will prove important for biosimilar drug sales from 2013 to 2023, our analyses show. Discover what the future holds.
Revenue prediction for the overall biosimilars market and its submarkets
Our report also forecasts revenues to 2023 for the world biosimilars industry and seven main segments:
• EPO
• Insulin
• Filgrastim
• Somatropin
• Interferons
• FSH
• Monoclonal antibodies (mAbs).
There you see overall world revenues in 2017 reaching $8.8bn. Our analyses reveal high sales growth from 2013 to 2023. That work also predicts large companies and specialty healthcare firms will develop and prosper.
Ways Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2013-2023 helps you
In particular, our new report gives you the following knowledge:
• Profiles of 25 leading companies – assess product ranges, strategies, and sales results, also gaining revenue forecasts to 2023 for 8 organisations
• Competition and opportunities – explore what affects the biosimilars market, finding what shapes its future, esp. prospects for sustaining and developing business
• Revenues to 2023 for that industry at world level, with forecasting of 7 submarkets – discover overall outlooks for commercial success.
Analysis found nowhere else – discover the future of those biologics
Our work gives independent analysis. There you receive competitive intelligence found only in our report. You discover where prospects are most rewarding.
With that investigation you're less likely to fall behind in knowledge or miss sales opportunity. See there how you could benefit your research, analysis, and decisions. Also find how you could save time and get recognition for understanding, increasing your influence.
Predictions for developing, producing, and selling biosimilars – gain by ordering now
Our new report shows you data, trends, opportunities, and outlooks for producers and sellers of biosimilars and related biological drugs. That analysis is for everybody interested in the future of biopharmaceuticals. Avoid missing out – please order now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
To view free sample pages of this report please click here
1. Executive Summary
1.1 Top Biosimilar Drug Manufacturers: Overview of Findings
1.2 Report Contents
1.3 Report Methods
1.4 Scope and Format of Report
2. The World Biosimilar Drugs Market, 2013-2023
2.1 Introduction to Biologics and Biosimilars: A Definition
2.1.1 Categorising Biologic and Biosimilar Drugs
2.2 The World Biosimilar Drugs Market, 2013-2023
2.2.1 The World Biosimilar Drugs Market, 2012
2.2.2 The World Biosimilar Drugs Market: Revenue Forecast, 2013-2023
2.2.3 How Will Market Shares of Leading Sectors Change from 2013-2023?
2.3 What Will Drive The World Biosimilar Drugs Market Between 2013 and 2023?
2.4 What Factors are Likely to Restrain the World Biosimilars Drugs Market Between 2013 and 2023?
2.5 Leading Companies in the World Biosimilars Market, 2012
2.5.1 How Will the Top 25 Ranking Change Between 2013 and 2023?
2.5.1.1 Which Companies Are Generating Interest in the Field?
3. Top Biosimilar Manufacturers Based in Developed National Pharma Markets, 2013-2023
3.1 Sandoz: The Biosimilars Market Leader, 2012
3.1.1 Three Biosimilars Marketed Worldwide
3.1.1.1 Omnitrope (Somatropin): A Global Biosimilar Brand
3.1.1.2 Binocrit (Epoetin Alpha): High Comparability to Reference Product
3.1.1.3 Zarzio (Filgrastim): Number 1 Biosimilar G-CSF in the World?
3.1.2 Strong Sales Prompts Revenue Growth for Sandoz, 2009-2012
3.1.3 Biosimilars R&D Pipeline, 2012
3.1.3.1 Biosimilar Rituximab: First to Market in the EU?
3.1.4 Sandoz: Biosimilars Market Outlook
3.1.4.1 Sandoz: Biosimilars SWOT Analysis, 2013-2023
3.1.4.2 Will Sandoz be the Biosimilars Market Leader in 2023?
3.2 Teva Pharmaceuticals
3.2.1 Biosimilar Product Portfolio
3.2.1.1 Tevagrastim (Filgrastim): First Biosimilar Filgrastim to be Approved in the EU
3.2.1.2 Eporatio (Epoetin Theta): A True Biosimilar?
3.2.1.3 Teva Acquires Ratiopharm to Strengthen Biosimilar Portfolio
3.2.1.4 Expansion in Eastern Europe: Teva Acquires Sicor Biotech
3.2.2 Oncology Biosimilars Drive Revenue Growth, 2010-2012
3.2.3 Teva to Launch Biosimilars in Growing Japanese Market
3.2.4 Biosimilars Pipeline, 2012
3.2.4.1 Teva Collaborates with Lonza to Develop Biosimilar Rituximab
3.2.4.2 Teva Will be First to Launch Biosimilar Filgrastim in the US
3.2.5 Teva: Biosimilars Market Outlook
3.2.5.1 Broad Market Access for Growth Opportunities
3.2.5.2 Comparing Teva's Revenue Growth with Sandoz, 2013-2023
3.3 Hospira
3.3.1 Biosimilar Product Portfolio: Company Posts Robust Sales Due to EPO Biosimilar
3.3.2 Which Biosimilar Products Hospira is Developing?
3.3.2.1 Biosimilars for the US Market
3.3.2.2 Alliance with Celltrion for Biosimilar Monoclonal Antibodies
3.3.3 Hospira: Biosimilars Market Outlook
3.3.3.1 Hospira: Biosimilars SWOT Analysis, 2013-2023
3.4 Stada Arzneimittel
3.4.1 Silapo (Epoetin Zeta): the Company's Biosimilar
3.4.2 Performance of Silapo in the EU, 2009-2012
3.4.3 Biosimilar Monoclonal Antibodies (mAbs) in Development
3.4.3.1 Collaboration with Gedeon Richter, 2011
3.4.4 Stada: Biosimilars Market Outlook
3.4.4.1 Alliances: In-House Development for Future Growth
3.4.4.2 Stada: Biosimilar Revenue Forecast, 2013-2023
3.5 Medice Arzneimittel Pütter
3.5.1 Medice Markets a Biosimilar in the EU
3.5.2 Medice Arzneimittel Pütter: Biosimilars Market Outlook
3.6 JCR Pharmaceuticals: Leading Japanese Market Player
3.6.1 Epoetin Alfa BS Inj. JCR: Japan's Second Biosimilar
3.6.2 Alliance with GSK: Helping to Distribute Treatments Overseas
3.6.3 Biosimilars Pipeline, 2012
3.6.4 JCR Pharmaceuticals: Biosimilars Market Outlook
3.7 New Market Entrants to Compete to 2023 - Rivalry in Industry
3.7.1 Watson Pharmaceuticals/Actavis Set to Enter Biosimilar Market
3.7.2 Mylan: Another Big Generics Manufacturer Developing Biosimilars
3.7.3 Biosimilar Specialists and Top Pharma Companies Grabbing Slices of the Pie
3.7.3.1 Pfizer: Exploiting Alliances and Internal Biosimilar Development for Market Entry
3.7.3.2 Boehringer Ingelheim: Specialist Division Established for Biosimilar Development
3.7.4 Domestic Manufacturers Looking to Enter the Japanese Market
3.7.4.1 Mochida Pharmaceutical: Biosimilar Filgrastim May Struggle with Market Competition
3.7.4.2 Nichi-Iko Pharmaceutical Partners with Sanofi for Biosimilars
3.7.4.3 Nippon Kayaku: Ambitious Future Biosimilar Revenue Rests on Clinical Trial Data
4. Top Chinese Biosimilar Manufacturers, 2013-2023
4.1 3SBio: China's Leading Biosimilars Manufacturer
4.1.1 Biosimilar Product Portfolio
4.1.1.1 EPIAO (Erythropoietin): Market-Leading EPO Product in China
4.1.1.2 TPIAO (Thrombopoietin: Loss of Market Exclusivity Will Lead to Launch of Rival Products
4.1.1.3 Intefen: Strong Correlation with Originator Drug Association
4.1.1.4 Inleusin: First Interleukin Product Approved in China
4.1.2 3SBio is Dominant in the Chinese EPO Market
4.1.3 Biosimilars Pipeline, 2012
4.1.4 3SBio: Biosimilars Market Outlook
4.1.4.1 How Will Novel Drug Development Affect 3SBio's Biosimilar Performance?
4.1.4.2 3SBio: Biosimilar Revenue Forecast, 2013-2023
4.2 Beijing SL Pharmaceutical
4.2.1 Specialising in Niche Biosimilars
4.2.2 Biosimilar Financial Performance, 2012
4.2.3 Biosimilars Pipeline, 2012
4.2.4 Beijing SL Pharmaceutical: Biosimilars Market Outlook
4.2.4.1 Targeting Monoclonal Antibodies for Future Growth
4.3 GeneScience Pharmaceuticals (GenSci)
4.3.1 Biosimilar Product Portfolio
4.3.1.1 Jintropin (Somatropin): A Low-Cost Growth Hormone
4.3.2 Three Biosimilars in Development, 2012
4.3.3 GeneScience Pharmaceuticals: Biosimilars Market Outlook
4.3.3.1 Product Launches in 2013-2014 to Drive Growth
4.4 Shanghai Fosun Pharmaceutical
4.4.1 Shanghai Fosun's Biosimilar Insulin
4.4.2 Rapid Revenue Growth, 2008-2009
4.4.3 Shanghai Fosun Pharmaceutical: Biosimilars Market Outlook
4.4.3.1 Will Insulin Analogues Maintain Shanghai Fosun's Market Share?
4.5 Tonghua Dongbao
4.5.1 Biosimilar Product Portfolio: Drug-Device Combinations May Open New Revenue Streams
4.5.2 Expanding Manufacturing Capacity to Cope with Increased Demand
4.5.3 Biosimilars Pipeline, 2012
4.5.4 Tonghua Dongbao: Biosimilars Market Outlook
4.5.4.1 Tonghua Dongbao to Launch Insulin Analogues in 2015
4.6 The Chinese Biosimilars Market is Competitive - Many New Companies Will Enter by 2023
4.6.1 Can United Laboratories Gain Significant Insulin Market Share?
4.6.2 Shanghai CP Goujian Pharmaceutical Leads Biosimilar Monoclonal Antibody Development
5. Top Indian Biosimilar Manufacturers, 2013-2023
5.1 Biocon
5.1.1 Biosimilar Product Portfolio
5.1.1.1 Basalog: Biocon's First Insulin Analogue
5.1.2 Construction of Dedicated Biosimilar Research Facility
5.1.3 Alliances for Entering Developed Markets
5.1.3.1 Biocon Acquires, and Sells, a Stake in AxiCorp
5.1.3.2 Pfizer: An Abandoned Biosimilar Insulin Collaboration
5.1.3.3 Biocon Partners with Mylan for Cancer-Treating Biosimilars
5.1.4 Biosimilars Pipeline, 2012
5.1.5 Biocon: Biosimilars Market Outlook
5.1.5.1 Insulin and Monoclonal Antibodies: Two Key Market Sectors to Drive Growth for Biocon
5.2 Dr. Reddy's Laboratories
5.2.1 Biosimilar Product Portfolio
5.2.1.1 Reditux (Rituximab): India's First Biosimilar Monoclonal Antibody
5.2.2 Biosimilar Revenue Growth Outpaces Generic Revenue Growth, 2011-2012
5.2.3 Alliance with Merck KGaA to Enter Developed Markets
5.2.4 Seven New Biosimilars to Launch by 2018
5.2.5 Dr. Reddy's Laboratories: Biosimilars Market Outlook
5.2.5.1 Opportunities Exist for Continued Biosimilar Growth, 2013-2023
5.2.5.2 Dr. Reddy's Laboratories: Rapid Revenue Growth, 2013-2023
5.3 Intas Biopharmaceuticals
5.3.1 Five Biosimilars Launched Since 2004
5.3.2 Filgrastim for Developed Markets: Alliance with Apotex
5.3.3 Intas Has the Longest Biosimilar Antibody Pipeline in India
5.3.4 Intas Biopharmaceuticals: Biosimilars Market Outlook
5.3.4.1 Biosimilars vs. Biobetters: Two Future Biological Drug Development Strategies
5.4 Reliance Life Sciences
5.4.1 Reliance Has Launched Seven Biosimilars in Three Years
5.4.2 Reliance GeneMedix: A Developed Market Subsidiary
5.4.3 Biosimilars Pipeline, 2012
5.4.4 Reliance Life Sciences: Biosimilars Market Outlook
5.4.4.1 Can Reliance Continue its Rapid Growth in the Biosimilars Market?
5.5 Wockhardt
5.5.1 Wockhardt: Focused on Biosimilar Insulin
5.5.1.1 Wosulin: Launch of Delivery Device Helps Drug Achieve National Status
5.5.1.2 Glaritus: The World's First Biosimilar Insulin Glargine
5.5.2 Biosimilars Pipeline, 2012
5.5.3 Wockhardt: Biosimilars Market Outlook
5.5.3.1 More Biosimilar Launches Expected Beyond 2015
5.6 Zydus Cadila
5.6.1 A Long History in Biosimilars
5.6.2 Seventeen Biosimilars and Two Novel Drugs in Pipeline, 2012
5.6.3 Zydus Cadila: Biosimilars SWOT Analysis, 2013-2023
5.7 More Generics Manufacturers Will Enter the Market from 2013
5.7.1 Ranbaxy Laboratories and Zenotech Laboratories Market Three Biosimilars
5.7.2 Cipla: Developing Biosimilars Since 2004
5.7.3 Lupin Pharmaceuticals: Venturing into Biosimilars to Strengthen High Reputation
6. Top Latin American Biosimilar Manufacturers, 2013-2023
6.1 Probiomed
6.1.1 Biosimilar Products Marketed Since 1998
6.1.2 Probiomed Plans to Enter the Brazilian Market
6.1.3 Patent Dispute Delayed Launch of Biosimilar Rituximab
6.1.4 Probiomed: Biosimilars Market Outlook
6.1.4.1 Expanding its Mature Biosimilar Portfolio to New Markets for Opportunities, 2013-2023
6.2 Biosidus
6.2.1 Decades of Experience in Biologics
6.2.2 Facility Expansion to Meet Increased Demand
6.2.3 Biosimilars in Late-Stage Development
6.2.4 Biosidus: Biosimilars Market Outlook, 2013-2023
6.2.4.1 Biosidus: Biosimilars SWOT Analysis, 2013-2023
6.3 Amega Biotech
6.3.1 Biosimilar Product Portfolio: Broad Indications
6.3.2 Investment in New Manufacturing Facilities, 2011-2012
6.3.3 Which New Biosimilars is Amega Biotech Developing?
6.3.4 Amega Biotech: Biosimilars Market Outlook
6.3.4.1 New Product Launches and New Markets as Growth Opportunities
6.4 Aché
6.4.1 Biosimilar Product Portfolio: Joint Venture with Biosidus for Manufacturing and Commercialisation
6.4.2 Bionovis: Collaboration for Revenue Growth
6.4.3 Biosimilars Pipeline, 2012
6.4.4 Aché: Biosimilars Market Outlook
6.4.4.1 How Will Aché's Biosimilar Portfolio Perform?
6.5 Latin America: Promising National Markets Giving Opportunities for Biosimilars Producers from 2013 to 2023
7. Top Biosimilar Manufacturers in Central and Eastern Europe (CEE) and the Russian Federation, 2013-2023
7.1 Bioton: Biosimilar Insulin for Emerging Markets
7.1.1 Biosimilar Product Portfolio
7.1.1.1 Gensulin: Collaboration with GSK Aims to Market Drug in Russia
7.1.1.2 Biosimilars in Developed Markets: Biopartners
7.1.1.3 Targeting Asia: Bioton's Partnership with SciGen
7.1.2 Insulin and Other Biosimilars: Revenue Performance, 2011-2012
7.1.3 Bioton and the Chinese Insulin Market
7.1.4 Alliance with Actavis to Bring Gensulin to Developed Markets
7.1.5 Bioton: Biosimilars Market Outlook
7.1.5.1 How Will Watson's Acquisition of Actavis Affect Bioton?
7.1.5.2 Bioton: Biosimilar Revenue Forecast, 2013-2023
7.2 Pharmstandard
7.2.1 Three Biosimilars Marketed in Russia
7.2.1.1 International Biotech Center (IBC) Generium
7.2.2 High Revenue Growth, 2010-2012
7.2.3 Pharmstandard Has Expanded its Market Presence Through Strategic Acquisitions
7.2.4 Pharmstandard: Biosimilars Market Outlook
7.2.4.1 Pharmstandard: Biosimilars SWOT Analysis, 2013-2023
7.2.4.2 Incorporation of New Subsidiaries to Stimulate Revenue Growth, 2013-2023
7.3 CEE and Russia: Biosimilar Competitor Analysis, 2013-2023
7.3.1 Gedeon Richter: Two Monoclonal Antibodies in Development
7.3.2 Egis Pharmaceuticals
8. Top South Korean Biosimilar Manufacturers, 2013-2023
8.1 LG Life Sciences: An Emerging Market Leader
8.1.1 Expertise in Fertility
8.1.2 How Have LG's Biosimilars Performed in Recent Years?
8.1.3 Three Biosimilar Monoclonal Antibodies in Development
8.1.4 LG Life Sciences: Biosimilars Market Outlook
8.1.4.1 LG Life Sciences: Biosimilars SWOT Analysis, 2013-2023
8.1.4.2 New Product Launches for Revenue Growth, 2013-2023
8.2 Dong-A Pharmaceutical
8.2.1 Biosimilar Product Portfolio
8.2.2 Revenue Growth in South Korea and Brazil, 2009-2012
8.2.3 Alliance with Meiji Seika Pharma to Enter the Japanese Market
8.2.4 Biosimilars Pipeline, 2012
8.2.4.1 DA-3031 (Pegfilgrastim): Lucrative G-CSF Market Drives Development of Biosimilar Drug for Neutropenia
8.2.5 Dong-A Pharmaceutical: Biosimilars Market Outlook
8.2.5.1 Dong-A Pharmaceutical: Biosimilars SWOT Analysis, 2013-2023
8.3 Many Companies Are Developing Biosimilar Monoclonal Antibodies in South Korea
8.3.1 Celltrion: A Partner for Many Biosimilar Developers Worldwide
8.3.2 Samsung Partners with Quintiles and Biogen Idec to Develop Biosimilars
9. Biosimilars: Industry Trends, 2013-2023
9.1 What Are the Strengths and Weaknesses of the Biosimilars Market in 2013?
9.2 Opportunities and Threats for Biosimilars Developers, 2013-2023
9.3 Biosimilars Market: STEP Analysis, 2013-2023
9.3.1 Social Factors: Raising Awareness will Lead to Greater Product Adoption
9.3.2 Technological Developments Will Simplify Biosimilar Production
9.3.3 Economic Pressures Driving Biosimilar Demand
9.3.4 Political Issues: Patent Challenges, Data Exclusivity and Regulatory Pathways
9.3.4.1 Regularly Updated Guidelines Will Benefit Developers
9.3.4.2 International Cooperation Necessary
10. Opinion from a Research Interview
10.1 Spokesperson from Biosidus
10.1.1 Current Biosimilars Business and Product Portfolio
10.1.2 Regional Competition Facing Biosidus
10.1.3 Future Strategies for Growth and Company Threats
11. Conclusions
11.1 Sandoz Leads the World Biosimilars Market, 2012
11.2 Outlook for Biosimilar Market Leaders, 2013-2023
11.3 New Entrants to The Market Will Increase Competition
List of Tables
Table 1.1 Currency Exchange Rates
Table 2.1 The World Biosimilar Drugs Market: Revenue ($m) and Market Share (%) by Medicine Type, 2012
Table 2.2 The World Biosimilar Drugs Market: Revenue Forecast ($m, AGR %, CAGR %) by Medicine Type, 2013-2023
Table 2.3 The World Biosimilar Drugs Market: Market Share (%) by Medicine Type, 2013-2023
Table 2.4 Top Ten Biosimilar Manufacturers: Estimated Revenue ($m) and Market Shares (%) by Company, 2012
Table 3.1 Leading Biosimilar Manufacturers in Developed Markets: Revenue ($m) and Market Share (%) by Company, 2012
Table 3.2 Sandoz: Key Facts, 2013
Table 3.3 Sandoz: Biosimilar Revenue ($m) by Product, 2009-2012
Table 3.4 Sandoz: Biosimilars SWOT Analysis, 2013-2023
Table 3.5 Sandoz: Biosimilar Revenue Forecast ($m, AGR %, CAGR %), 2013-2023
Table 3.6 Teva: Key Facts, 2013
Table 3.7 Teva: Biosimilar Revenue ($m) by Type, 2010-2012
Table 3.8 Teva: Biosimilars SWOT Analysis, 2013-2023
Table 3.9 Teva: Biosimilar Revenue Forecast ($m, AGR %, CAGR %), 2013-2023
Table 3.10 Hospira: Key Facts, 2013
Table 3.11 Hospira: Biosimilars SWOT Analysis, 2013-2023
Table 3.12 Stada: Key Facts, 2013
Table 3.13 Stada: Biosimilar Revenue ($m, AGR %, CAGR %), 2009-2012
Table 3.14 Stada: Biosimilars SWOT Analysis, 2013-2023
Table 3.15 Stada: Biosimilar Revenue Forecast ($m, AGR %, CAGR %), 2013-2023
Table 3.16 Medice: Key Facts, 2013
Table 3.17 JCR Pharmaceuticals: Key Facts, 2013
Table 3.18 JCR Pharmaceuticals: Biosimilars SWOT Analysis, 2013-2023
Table 3.19 Big Pharma and the Biosimilars Market, 2013
Table 4.1 Selected Chinese Biosimilar Manufacturers and their Activities, 2013
Table 4.2 3SBio: Key Facts, 2013
Table 4.3 3SBio: Biosimilar Revenue ($m, CAGR %) by Product, 2010-2012
Table 4.4 3SBio: Biosimilars SWOT Analysis, 2013-2023
Table 4.5 3SBio: Biosimilar Revenue Forecast ($m, AGR %, CAGR %), 2013-2023
Table 4.6 Beijing SL Pharmaceutical: Key Facts, 2013
Table 4.7 Beijing SL Pharmaceutical: Biosimilars SWOT Analysis, 2013-2023
Table 4.8 GeneScience Pharmaceuticals: Key Facts, 2013
Table 4.9 GeneScience Pharmaceuticals: Biosimilars SWOT Analysis, 2013-2023
Table 4.10 Shanghai Fosun Pharmaceutical: Key Facts, 2013
Table 4.11 Chinese Insulin Market: Market Share (%) by Company, 2012
Table 4.12 Wanbang Biopharmaceuticals: Revenue ($m) and Growth (%), 2009 & 2011
Table 4.13 Shanghai Fosun Pharmaceutical: Biosimilars SWOT Analysis, 2013-2023
Table 4.14 Tonghua Dongbao: Key Facts, 2013
Table 4.15 Tonghua Dongbao: Biosimilars SWOT Analysis, 2013-2023
Table 5.1 Biocon: Key Facts, 2013
Table 5.2 Biocon: Biosimilars SWOT Analysis, 2013-2023
Table 5.3 Biocon: Biosimilar Reported Discounts (%), 2012
Table 5.4 Dr. Reddy's Laboratories: Key Facts, 2013
Table 5.5 Dr. Reddy's Laboratories: Biosimilar Portfolio, 2013
Table 5.6 Reditux: Revenue ($m, AGR %, CAGR %) 2009-2013
Table 5.7 Dr. Reddy's Laboratories: Biosimilar Revenues ($m) and Revenue Shares (%) in India, FY2011-FY2013
Table 5.8 Dr. Reddy's Laboratories: Biosimilars SWOT Analysis, 2013-2023
Table 5.9 Dr. Reddy's Laboratories: Biosimilar Revenue Forecast ($m, AGR %, CAGR %), 2013-2023
Table 5.10 Intas Biopharmaceuticals: Key Facts, 2013
Table 5.11 Intas Biopharmaceuticals: Biosimilar Product Portfolio, 2013
Table 5.12 Intas Biopharmaceuticals: Biosimilar Clinical Trials, 2012
Table 5.13 Intas Biopharmaceuticals: Biosimilars SWOT Analysis, 2013-2023
Table 5.14 Reliance Life Sciences: Key Facts, 2013
Table 5.15 Reliance Life Sciences: Biosimilar Product Portfolio, 2013
Table 5.16 Reliance Life Sciences: Biosimilars SWOT Analysis, 2013-2023
Table 5.17 Wockhardt: Key Facts, 2013
Table 5.18 Wockhardt: Biosimilars SWOT Analysis, 2013-2023
Table 5.19 Zydus Cadila: Key Facts, 2013
Table 5.20 Zydus Cadila: Biosimilar Product Portfolio, 2012
Table 5.21 Zydus Cadila: Biosimilar Pipeline, 2012
Table 5.22 Zydus Cadila: Biosimilars SWOT Analysis, 2013-2023
Table 6.1 Regulatory Policy and Clinical Trials in Leading Latin American Countries, March 2013
Table 6.2 Landsteiner Scientific: Marketed Biopharmaceuticals, 2012
Table 6.3 Probiomed: Key Facts, 2013
Table 6.4 Probiomed: Revenue ($m, AGR %, CAGR %), 2009-2012
Table 6.5 Probiomed: Biosimilars SWOT Analysis, 2013-2023
Table 6.6 Biosidus: Key Facts, 2013
Table 6.7 Biosidus: Biosimilars SWOT Analysis, 2013-2023
Table 6.8 Amega Biotech: R&D and Manufacturing Facilities, 2012
Table 6.9 Amega Biotech: Key Facts, 2013
Table 6.10 Amega Biotech: Revenue ($m) and Growth (%), 2011-2012
Table 6.11 Amega Biotech: Biosimilars SWOT Analysis, 2013-2023
Table 6.12 Aché: Key Facts, 2013
Table 6.13 Aché: Biosimilars SWOT Analysis, 2013-2023
Table 7.1 Bioton: Key Facts, 2013
Table 7.2 SciGen: Revenue ($m) and Revenue Share (%) by Country, 2012
Table 7.3 Bioton: Biosimilar Revenue ($m) and Growth (%) by Company, 2011-2012
Table 7.4 Bioton: Biosimilars SWOT Analysis, 2013-2023
Table 7.5 Bioton: Biosimilar Revenue Forecast ($m, AGR %, CAGR %), 2013-2023
Table 7.6 Pharmstandard: Key Facts, 2013
Table 7.7 Pharmstandard: Insulin Manufacturing Capacity, 2011-2012
Table 7.8 Pharmstandard: Biosimilar Revenue ($m, CAGR %) by Product, 2010-2012
Table 7.9 Pharmstandard: Biosimilars SWOT Analysis, 2013-2023
Table 7.10 Pharmstandard: Biosimilar Revenue Forecast ($m, AGR %, CAGR %), 2013-2023
Table 8.1 LG Life Sciences: Key Facts, 2013
Table 8.2 LG Life Sciences: Biosimilar Revenue ($m) and Growth (%) by Product, 2011-2012
Table 8.3 LG Life Sciences: Biosimilars SWOT Analysis, 2013-2023
Table 8.4 LG Life Sciences: Biosimilar Revenue Forecast ($m, AGR %, CAGR %), 2013-2023
Table 8.5 Dong-A Pharmaceutical: Key Facts, 2013
Table 8.6 Growtropin: Revenue ($m, AGR %, CAGR %), 2009-2012
Table 8.7 Dong-A Pharmaceutical: Growtropin Biosimilar Export Revenue ($m, CAGR %), 2009-2012
Table 8.8 Dong-A Pharmaceutical: Biosimilars SWOT Analysis, 2013-2023
Table 8.9 Celltrion: Biosimilar Licensing Deals, 2009-2010
Table 9.1 World Biosimilar Drug Market: Strengths and Weaknesses, 2013
Table 9.2 World Biosimilar Drugs Market: Opportunities and Threats, 2013-2023
Table 9.3 World Biosimilar Drugs Market: STEP Analysis, 2013-2023
Table 11.1 World Biosimilar Drugs: Market Shares (%) of Leading Companies, 2012, 2017 and 2023
List of Figures
Figure 2.1 The World Biosimilar Drugs Market: Share (%) by Medicine Type, 2012
Figure 2.2 The World Biosimilar Drugs Market: Overall Revenue Forecast ($m), 2013-2023
Figure 2.3 The World Biosimilar Drugs Market: Share (%) by Medicine Type, 2017
Figure 2.4 The World Biosimilar Drugs Market: Share (%) by Medicine Type, 2023
Figure 2.5 World Biosimilar Drugs Market: Drivers and Restraints, 2013-2023
Figure 2.6 Top Ten Biosimilar Manufacturers: Estimated Market Shares (%) by Company, 2012
Figure 3.1 Leading Biosimilar Manufacturers in Developed Markets: Share (%) by Company, 2012
Figure 3.2 Sandoz: Biosimilar Revenue ($m) by Product, 2009-2012
Figure 3.3 Sandoz: Biosimilar Revenue Forecast ($m), 2013-2023
Figure 3.4 Sandoz: Biosimilars Market Share (%), 2012, 2017 and 2023
Figure 3.5 Teva: Biosimilar Revenue ($m) by Type, 2010-2012
Figure 3.6 Teva: Biosimilar Revenue Forecast ($m), 2013-2023
Figure 3.7 Teva: Biosimilars Market Share (%), 2012, 2017 and 2023
Figure 3.8 Stada: Biosimilar Revenue ($m), 2009-2012
Figure 3.9 Stada: Biosimilar Revenue Forecast ($m), 2013-2023
Figure 3.10 Stada: Biosimilars Market Share (%), 2012, 2017 and 2023
Figure 3.11 Developed Markets: Biosimilar Rituximab Development, 2012
Figure 4.1 3SBio: Biosimilar Revenue Share (%) by Product, 2012
Figure 4.2 3SBio: Biosimilar Revenue Forecast ($m), 2013-2023
Figure 4.3 3SBio: Biosimilars Market Share (%), 2012, 2017 and 2023
Figure 4.4 Chinese Insulin Market: Share (%) by Company, 2012
Figure 4.5 Wanbang Biopharmaceuticals: Revenue ($m), 2009-& 2011
Figure 5.1 Reditux: Revenue ($m), 2009-2013
Figure 5.2 Dr. Reddy's Laboratories: Biosimilar Revenues ($m) and Revenue Shares (%) in India, FY2011-FY2013
Figure 5.3 Dr. Reddy's Laboratories: Biosimilar Revenue Forecast ($m), 2013-2023
Figure 5.4 Dr. Reddy's Laboratories: Biosimilars Market Share (%), 2012, 2017 and 2023
Figure 6.1 Probiomed: Biosimilar Launches, 1998-2004
Figure 6.2 Probiomed: Revenue ($m), 2009-2012
Figure 6.3 Amega Biotech: Revenue ($m), 2011-2012
Figure 7.1 SciGen: Revenue Share (%) by Country, 2012
Figure 7.2 Bioton: Biosimilar Revenue ($m) by Company, 2011-2012
Figure 7.3 Bioton: Biosimilar Revenue Forecast ($m), 2013-2023
Figure 7.4 Bioton: Biosimilars Market Share (%), 2012, 2017 and 2023
Figure 7.5 Pharmstandard: Biosimilar Revenue ($m) by Product, 2010-2012
Figure 7.6 Pharmstandard: Biosimilar Revenue Forecast ($m), 2013-2023
Figure 7.7 Pharmstandard: Biosimilars Market Share (%), 2012, 2017 and 2023
Figure 8.1 LG Life Sciences: Biosimilar Revenue ($m) by Product, 2011-2012
Figure 8.2 Biosimilar Monoclonal Antibody Progress in South Korea, 2012
Figure 8.3 LG Life Sciences: Biosimilar Revenue Forecast ($m), 2013-2023
Figure 8.4 LG Life Sciences: Biosimilars Market Share (%), 2012, 2017 and 2023
Figure 8.5 Growtropin: Revenue ($m), 2009-2012
Figure 8.6 Dong-A Pharmaceutical: Growtropin Biosimilar Export Revenue ($m), 2009-2012
Figure 9.1 Biosimilar Start-Up and Development Cost Estimates ($m), 2013
Figure 11.1 Biosimilars Market Leaders: Market Shares (%), 2012, 2017 and 2023
To view free sample pages of this report please click here
